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Objective: Primary and secondary pulmonary hypertension have been
associated with poor outcomes after single lung transplantation. Some
groups advocate double lung transplantation and the routine use of car-
diopulmonary bypass during transplantation in this population.
However, the optimal procedure for these patients remains controver-
sial. The goal of our study was to determine the safety of single lung
transplantation without cardiopulmonary bypass in patients with sec-
ondary pulmonary hypertension. Methods: We retrospectively reviewed
76 consecutive patients with pulmonary parenchymal disease who
underwent single lung transplantation from 1992 to 1998. Recipients
were stratified according to preoperative mean pulmonary artery pres-
sure. Secondary pulmonary hypertension was defined as parenchymal
lung disease with a preoperative mean pulmonary artery pressure of 30
mm Hg or more. Patients with primary pulmonary hypertension or
Eisenmenger’s syndrome were excluded from analysis. Results: Eighteen
of 76 patients had secondary pulmonary hypertension. No patient with
secondary pulmonary hypertension required cardiopulmonary bypass,
whereas 1 patient without pulmonary hypertension required bypass.
After the operation, no significant differences were seen in lung injury
as measured by chest radiograph score and PaO2/FIO2 ratio, the require-
ment for inhaled nitric oxide, the length of mechanical ventiliation, the
intensive care unit or hospital length of stay, and 30-day survival. There
were no differences in the forced expiratory volume in 1 second or 6-
minute walk at 1 year, or the incidence of rejection, infection, or bron-
chiolitis obliterans syndrome greater than grade 2. Survival at 1, 2, and
4 years after transplantation was 86%, 79%, and 65%, respectively, in
the low pulmonary artery pressure group and 81%, 81%, and 61%,
respectively, in the group with secondary pulmonary hypertension (P >
.2). Conclusion: We found that patients with pulmonary parenchymal dis-
ease and concomitant secondary pulmonary hypertension had success-
ful outcomes as measured by early and late allograft function and
appear to have acceptable long-term survival after single lung trans-
plantation. Our results do not support the routine use of cardiopul-
monary bypass or double lung transplantation for patients with this dis-
order. (J Thorac Cardiovasc Surg 2000;119:458-65)
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L ung transplantation is a viable therapeutic strategyfor patients with end-stage pulmonary parenchymal
and vascular disease.1-4 Controversy exists regarding
the optimal procedure for patients with primary or sec-
ondary pulmonary hypertension (PHTN). Because of
an elevated pulmonary vascular resistance (PVR) in the
native lung, patients undergoing single lung transplan-
tation (SLT) for pulmonary hypertensive disorders may
not tolerate allograft reperfusion injury and may expe-
rience increased perioperative morbidity and death
compared with patients without pulmonary hyperten-
sion. Long-term allograft function has also been report-
ed to be suboptimal after SLT for PHTN.5 This has led
some centers to recommend routine sequential double
lung transplantation (DLT) and cardiopulmonary
bypass (CPB) in patients with elevated preoperative
pulmonary artery pressures (PAPs).5,7 Because earlier
reports have dealt with either isolated pulmonary vas-
cular disease or have combined patients with primary
and secondary PHTN, these recommendations remain
controversial for patients with secondary PHTN. We
reviewed our experience to evaluate whether SLT in
patients with moderate secondary PHTN can be per-
formed safely without CPB.
Methods
Patient population and definition of secondary PHTN.
We retrospectively reviewed the case histories of 76 consecu-
tive patients who underwent SLT for pulmonary parenchymal
disease at the University of Colorado Health Sciences Center
between July 1992 and June 1998. Patient characteristics and
preoperative diagnoses are detailed in Table I. Recipients
were stratified according to PAPs into high PAP or low PAP
groups. Secondary PHTN was defined as the presence of
parenchymal lung disease and a mean PAP of 30 mm Hg or
more. Within the low PAP group (n = 58 patients), 28 patients
had chronic obstructive pulmonary disease, 11 patients had
α-1-antitrypsin deficiency, and 19 patients had idiopathic pul-
monary fibrosis. Within the secondary PHTN group (n = 18
patients), 12 patients had chronic obstructive pulmonary dis-
ease, 1 patient had α-1-antitrypsin deficiency, and 5 patients had
idiopathic pulmonary fibrosis. Patients with primary PHTN or
Eisenmenger’s syndrome were excluded from analysis.
Donor selection and perioperative management. Donors
were evaluated and deemed acceptable on the basis of previ-
ously published criteria.13 Acceptable donor criteria included
age less than 60 years, no history of pulmonary disease, PaO2
greater than 300 mm Hg on an inspired oxygen fraction (FIO2)
of 1.0 and a positive end-expiratory pressure of 5 cm H2O,
clear chest radiograph, negative sputum Gram stain, and an
unremarkable bronchoscopic examination. Preservation of
pulmonary allografts was performed with modified Euro-
Collins solution and central venous alprostadil (prostaglandin
E1; 500 µg) infusion. Recipients underwent standard pul-
monary function testing, echocardiography, right and left
radionuclide ventriculography, and right heart catheterization
before the transplantation. PAPs and right ventricular func-
tion were not used as exclusionary factors for SLT. Coronary
arteriography was performed for candidates over 40 years of
age. Donor lungs were matched to recipients by ABO com-
patibility, height and weight, and vertical and inframammary
circumferential dimensions within 20% of the recipient dimen-
sions. Operative techniques were as previously described.14
DLTs are not performed a priori for secondary PHTN at
our institution but rather are chosen for the classic indication
of septic lung disease or young patients with α-1-antitrypsin
deficiency. CPB or inhaled nitric oxide is used only when
mandated by hemodynamic instability, inadequate gas
exchange, or technical difficulty.
Patients received standard triple-drug immunosuppression
with cyclosporine (INN: ciclosporin), azathioprine, and pred-
nisone and did not receive lympholytic agents for induction.
Methylprednisolone (Solu-Medrol) 500 mg/kg was given
intravenously immediately before allograft reperfusion, then
125 mg intravenously every 12 hours for 6 doses. Prednisone
was then given at 1 mg/kg per day and tapered to 0.1 to 0.15
mg/kg per day by 1 month. Cyclosporine was maintained at
trough levels of 350 to 450 ng/dL, and azathioprine was given
at up to 2.5 mg/kg per day to maintain a whole white blood
cell count of 5000 cells/µL.
Assessment of early allograft function. The degree of
reperfusion injury was measured by chest radiography scores
and gas exchange. Chest radiographs were obtained at 0, 24,
and 48-hour intervals after the operation. The allograft was
divided on chest radiograph into upper and lower halves, and
each was scored as follows: 0, normal findings; 1, perihilar or
localized infiltrate; and 2, diffuse moderate to severe intersti-
tial and alveolar infiltrate. The halves were then added to give
a chest radiography score of 0 to 4. Each radiograph was
interpreted by a single radiologist at our institution who was
blinded to the intent of the study. Arterial blood gases were
obtained at 0 and 24 hours after the transplantation and used
to calculate the PaO2/FIO2 ratio. The need for postoperative
inhaled nitric oxide, length of mechanical ventilation, inten-
sive care unit and hospital length of stay, and patient survival
at 30 days were recorded. Pulmonary hemodynamics were
measured by balloon-tipped pulmonary artery catheter and
compared with preoperative values.
Assessment of late allograft function. Postoperative
forced expiratory volume in 1 second (FEV1) and 6-minute
walk distance were recorded at frequent intervals and report-
ed at 1 year. The incidence of acute rejection episodes and
infections was documented. The incidence of bronchiolitis
obliterans of more than grade 2 was determined by routine
postoperative pulmonary function tests or by its presence on
transbronchial biopsy. Acute and chronic rejection were grad-
ed according to International Society for Heart and Lung
Transplantation criteria.15 Survival was reported at 1, 2, and
4 years.
Statistical analysis. Preoperative and postoperative vari-
ables were compared with the use of analysis of variance and
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the Scheffé test. Results are stated as mean ± standard devia-
tion. Survival and the incidence of acute and chronic rejection
and infection were compared with the use of Kaplan-Meier
analysis.
Results
Patient population and perioperative characteris-
tics. Table I depicts the patient characteristics and their
preoperative diagnoses. Table II depicts preoperative
hemodynamic values and the severity of PHTN. We
found that 18 patients had elevated PAPs and that 58
patients had low PAPs. Systolic and mean PAPs were
significantly higher in the elevated PAP group than in
the low PAP group (systolic PAP, 45.2 ± 3.6 mm Hg vs
30.1 ± 5.6 mm Hg, respectively; mean PAP, 30.1 ± 4.4
mm Hg vs 18.5 ± 4.4 mm Hg, respectively; P = .0001).
PVR was significantly elevated in the high PAP versus
the low PAP group (332 ± 65.2 dynes · sec · cm–5 vs
192.2 ± 69.7 dynes · sec · cm–5; P = .001). There were
no significant differences between groups with regard
to age, sex, or indication for transplantation. Among
the 76 SLT recipients, 28 recipients received right lung
allografts and 48 recipients received left lung allo-
grafts. A similar percentage in each group received
right lung allografts. There were no intraoperative
deaths. CPB was used in 1 patient in the low PAP group
because of intraoperative hemorrhage but was not
required for any patient in the elevated PAP group.
Inhaled nitric oxide was used intraoperatively in 1
patient in the low PAP group to avoid CPB.
Early and late allograft function. There were no
significant differences in early allograft function mea-
sured by chest radiography injury scores (Fig 1, A),
PaO2/FIO2 ratios (Fig 1, B), length of mechanical venti-
lation (50.8 ± 53.6 hours in the low PAP group vs 49.2
± 54.1 hours in the high PAP group; P > .2), intensive
care unit stay (80.0 ± 53.5 hours in the low group vs
77.3 ± 32.5 hours in the elevated group; P > .2), or hos-
pital length of stay (14.6 ± 3.8 days in the low PAP
group vs 11.9 ± 5.8 days in the elevated group). After
the operation, systolic PAP and mean PAP fell signifi-
cantly in the high PAP group (systolic PAP, 45.2 ± 0.9
mm Hg to 32.1 ± 1.6 mm Hg; mean PAP, 30.9 ± 1.0
mm Hg to 21.6 ± 1.4 mm Hg; P < .004; Fig 2). There
were no significant changes in pulmonary pressures in
the low PAP group (systolic PAP, 30.1 ± 0.7 mm Hg to
27.8 ± 0.7 mm Hg; mean PAP, 18.5 ± 0.6 mm Hg to
17.6 ± 0.5 mm Hg; P > .2). There was a significant fall
in PVR in both groups after the transplantation (high
PAP, 332 ± 65.2 dynes · sec · cm–5 to 206.1 ± 52 dynes
Table I. Preoperative diagnoses and characteristics of 76 patients who underwent SLT (P > .2)
Low PAP group (n = 58) Elevated PAP group (n = 18)
Age (y) 50.6 ± 9.7 (26-69) 52.3 ± 6.1 (45-68)
M/F (n) 29/29 10/8
Allograft side, right/left (n) 21/37 7/11
Preoperative diagnosis (n)
Chronic obstructive pulmonary disease (%) 28 (48) 12 (67)
α1-Antitrypsin (%) 11 (19) 1 (6)
Idiopathic pulmonary fibrosis (%) 19 (33) 5 (28)
Need for CPB/inhaled nitric oxide 1/1 0
Table II. Preoperative hemodynamic comparison and severity of PHTN in low and elevated PAP groups
Low PAP group (n = 58) Elevated PAP group (n = 18)
Systolic PAP (mm Hg) 30.1 ± 5.6 45.2 ± 3.6*
Range 14-37 38-56
Mean PAP (mm Hg) 18.5 ± 4.4 30.1 ± 4.4*
Range 9-29 30-39
Severity of PHTN (n)
Mild† 0
Moderate‡ 18
Severe§ 0
PVR (dynes · sec · cm–5) 192.2 ± 69.7 332 ± 65.2*
*P = .001.
†Mean PAP, 25-29.
‡Mean PAP, 30-39.
§Mean PAP, ≥40.
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· sec · cm–5; P = .0001; low PAP, 192.2 ± 69.7 dynes ·
sec · cm–5 to 164.2 ± 41.5 dynes · sec · cm–5; P = .007).
Postoperative inhaled nitric oxide was used in 5
patients in the low PAP group (8%) and 2 patients in the
elevated PAP group (11%) because of allograft dys-
function (P > .2). There were 2 early deaths in each
group, yielding survivals at 30 days of 95% in the low
PAP group and 89% in the elevated PAP group (P > .2).
The overall incidence of acute rejection was 0.30
episodes per 100 patient-days in the low PAP group and
0.35 episodes per 100 patient-days in the elevated PAP
group (P > .2; Fig 3, A). Infection in the low PAP group
was 0.30 episodes per 100 patient-days and 0.45
episodes per 100 patient-days in the high PAP group (P
> .2; Fig 3, B). There were no significant differences in
long-term allograft function as measured by FEV1 and
6-minute walk distance at 1-year after the transplanta-
tion (Fig 4). Finally, bronchiolitis obliterans of more
than grade 2 (diagnosed by pulmonary function test cri-
teria or transbronchial biopsy) was found in 37% in the
low PAP group and in 33% of the elevated PAP group
(P > .2). Mean time to diagnosis of bronchiolitis oblit-
Fig 1. Comparison of early allograft function by postoperative chest radiography (CXR) injury scores (A) and
PaO2/FIO2 ratios (B) between the low (black bar) and elevated (open bar) PAP groups (P > .2).
A B
Fig 2. Postoperative change in systolic PAP (A) and mean PAP (B) in low and elevated PAP groups. *P = .0001
high vs low. **P = .0004 vs preoperative value.
A B
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erans syndrome (BOS) of more than grade 2 was 28.0
± 4.7 months in the high PAP group and 26.3 ± 4.0
months in the low PAP group (P > .2; Fig 5).
Survival. The 1-, 2-, and 4-year survivals after trans-
plantation for patients in the low PAP group were 86%,
79%, and 65% and in the elevated PAP group, 81%,
81%, and 61%, respectively (P > .2; Fig 6).
Discussion
Several groups have shown that SLT for PHTN is
associated with increased morbidity and death and that
long-term allograft function and survival may be sub-
optimal.4,8 This has led some centers to recommend
sequential DLT and the use of CPB in all patients with
pretransplantation elevation of PAPs.5,7,9 Many of these
previous reports dealt with primary PHTN or combined
the outcomes of patients with primary and secondary
PHTN into 1 group. When analyzed separately, patients
with secondary PHTN have similar 12- and 18-month
survivals compared with patients without PHTN.6
However, these patients may still have increased intra-
operative and perioperative complications. Preliminary
observations by Park and colleagues7 revealed that SLT,
in patients with pulmonary parenchymal disease and
elevated preoperative PAPs (systolic PAP ≥40 mm Hg),
was associated with an 8.5-fold increase in the need for
A B
Fig 3. Comparison of incidence of acute rejection (A) and acute infection (B) in low (black bar) versus elevated
(open bar) PAP groups (P > .2).
A B
Fig 4. FEV1 (A) and 6-minute walk (B) at 1 year in low (black bar) and elevated (open bar) PAP groups (P > .2).
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CPB. Further, they found a markedly diminished 3-year
survival of 34% versus 77% in patients without sec-
ondary PHTN. They concluded that secondary PHTN is
an independent risk factor for diminished patient sur-
vival and the need for CPB. In the present study, we
found that patients undergoing SLT for pulmonary
parenchymal diseases with moderate PHTN did not
have an increased requirement for CPB or early allo-
graft dysfunction compared with patients with sec-
ondary PHTN. Further, we found no differences in long-
term survival or allograft function between groups.
PHTN is associated with pulmonary vasoconstric-
tion, vasoproliferation, and a subsequent increase in
PVR. After SLT, this increased PVR in the native lung
diverts 85% to 100% of the perfusion to the allograft.
Reperfusion injury may lead to increased ventilation-
perfusion mismatching and gas exchange abnormalities
compared with a similar degree of injury in patients
who are able to more equally distribute pulmonary
blood flow between the allograft and the native lung.
For this reason, some consider SLT in the setting of
PHTN to be contraindicated. However, Boujoukos,11
and Sheridan,12 and their colleagues have shown that
preferential blood flow to the allograft does not in itself
enhance reperfusion injury and that early and late allo-
graft function is maintained. The present study also
Fig 5. Percentage of freedom from BOS of more than grade 2 in low (dashed line) and elevated (solid line) PAP
groups (P > .2). Confidence limits: 1-year (low group, 0.97 to 0.78; high group, 0.96 to 0.76) and 3-year (low
group, 0.77 to 0.46; high group, 0.86 to 6.66).
Fig 6. Survival curves by Kaplan-Meier method for low (dashed line) versus elevated (solid line) PAP groups (P
> .2). Confidence limits: 1-year (low group, 0.95 to 0.77; high group, 1.0 to 0.62); 3-year (low group, 0.86 to 0.62;
high group, 1.0 to 0.62); and 4-year (low group, 0.80 to 0.50; high group, 0.95 to 0.26).
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supports the finding that, in the setting of PHTN, pref-
erential blood flow to the allograft does not augment
reperfusion injury and that the mechanism behind
reperfusion injury in the setting of PHTN is multifac-
torial. Therefore routine use of DLT may not provide a
significant early physiologic or functional advantage in
patients with moderate PHTN.
There are a number of theoretic advantages of DLT
over SLT for pulmonary hypertensive disorders. DLT
provides more pulmonary reserve that SLT. Therefore
patients in whom BOS develops after DLT may toler-
ate chronic rejection better than patients who undergo
SLT. DeHoyos and colleagues2 have also reported a
possible increased incidence of BOS after SLT for
PHTN. We did not find this to be the case in our
patients. The incidence of and the time to onset of BOS
were similar in both groups in our study. The incidence
of BOS may in fact be identical in SLT versus DLT but
may be detected earlier in SLT patients because of the
smaller pulmonary reserve. This same group also
reported decreased long-term survival in SLT versus
DLT for PHTN. The advantages of SLT over DLT are
shorter ischemia times and maximal use of available
donor lungs. The present study was not designed to
compare the outcomes of SLT versus DLT for PHTN.
Gammie and colleagues6 have recently reported that,
in their 8-year experience of SLT versus DLT for pri-
mary and secondary PHTN, they found similar mortal-
ity and long-term outcomes in each group. Although
theirs is not a randomized trial, they cautiously sup-
ported the use of SLT for patients with PHTN. A sig-
nificant difference between their experience and ours is
the apparent routine use of CPB for all patients with
underlying PHTN. CPB during lung transplantation
may itself lead to allograft injury. Aeba and col-
leagues10 demonstrated these undesirable effects in
patients who underwent SLT or DLT for a variety of
underlying conditions. They concluded that the use of
CPB led to impaired oxygenation, prolonged intuba-
tion, enhanced lung injury, and diminished 1-month
survival. Therefore the avoidance of CPB may provide
substantial benefit to patients in regard to limiting
reperfusion injury, postoperative hemodynamic stabili-
ty, ease of extubation, and overall allograft perfor-
mance. We use bypass only if mandated by hemody-
namic instability, inadequate gas exchange, or
technical difficulty during the operation. We have also
found that inhaled nitric oxide may be effective in pre-
venting the need for CPB during an operation.
The discrepancy between our results and those of
other centers may be due to the fact that we only
reviewed patients with secondary PHTN of a moderate
level, whereas earlier reports included patients with
both primary and secondary PHTN. These groups may
not be directly comparable. Pathologically, primary
PHTN is associated with plexogenic arterial lesions,
and secondary PHTN is associated with predominantly
vascular smooth muscle cell proliferation. Physio-
logically, when compared with secondary PHTN, pri-
mary PHTN is associated with a more rapid progres-
sion, a more severe decrease in right ventricular ejection
fraction, and a more severe fall in cardiac output with
exercise. Finally, patients who undergo transplantation
for primary PHTN typically have near-systemic PAPs
and mean PAPs in excess of 50 to 60 mm Hg. All of our
patients with secondary PHTN had mean PAPs between
30 and 40 mm Hg and would be classified as having
moderate PHTN. Alternatively, the difference may be
due to the low number of patients in our elevated PAP
group (n = 18 patients). A type II (β) error may be pres-
ent, and we are unable to detect a difference between
these groups at this time. However, in a similar-sized
group of patients with secondary PHTN, Park and col-
leagues7 found markedly different results than ours.
Perhaps there are other unstated differences in donor
and recipient selection or in intraoperative and postop-
erative management strategies that account for the
observed differences between their study and ours.
Finally, the lack of prospective randomization of
patients to SLT versus DLT with or without the use of
CPB could have introduced inherent bias into this study.
In summary, we found that patients with pulmonary
parenchymal disease and concomitant secondary
PHTN have successful outcomes regarding early and
late allograft function and appear to have acceptable
long-term survival after SLT. Our results do not support
the routine use of CPB or DLT in patients with sec-
ondary PHTN. The use of SLT in this patient popula-
tion not only provides adequate outcomes but also
makes maximal use of the available donor pool by lim-
iting the use of DLT to younger patients or those with
septic lung diseases who have no other alternatives in
the choice of lung transplantation procedure.
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Discussion
Dr Vaughn A. Starnes (Los Angeles, Calif). One of the
things that I have taken away from this article is trying to
redefine what is meant by secondary PHTN. We see excellent
results in a group of patients who had primary parenchymal
lung disease and some resulting mild hypertensive changes in
a small group of those patients. As we look at this issue, and
this topic has been discussed in the literature for 5 to 6 years,
the implication when I first saw the title was that PHTN did
not affect the need for DLT. At the end of the article, I felt as
if SLT was an effective therapy for parenchymal lung disease. 
What was the PVR in this group of patients in the moder-
ate hypertensive group? Did you look at any of these results
in a postoperative period of time as it relates to perfusion
scanning; that is, did the allograft have most of the perfusion
going to it or a balance of perfusion, as would be indicated by
your PaO2/FIO2 ratio? 
The whole issue concerning SLT for primary or secondary
PHTN has been in the area of a vascular lesion and not a
parenchymal lung lesion. That is really what we are dealing
with today, a parenchymal lung lesion.
Dr Huerd. We did measure the PVR in each patient pre-
operatively but did not routinely evaluate changes in PVR
over time. To answer your question regarding the evidence of
equivalent gas exchange based on our pulmonary function
and perfusion studies between the two sides, we did not rou-
tinely follow up on those patients with perfusion scans to
determine whether our allograft received 50%, 70%, or 90%
of the flow. We did make the assumption that because their
pressures were lower than what you would see in a patient
with primary PHTN, the flow would probably be equivalent-
ly distributed between the two lungs and that the native lung
significantly participated in gas exchange postoperatively. 
Dr Starnes. Did you know whether these patients had
PHTN preoperatively? If so, did that prejudice your donor
selection for these particular recipients? 
Dr Huerd. No. On the basis of our preoperative evaluation
of each patient, we did know their preoperative PAP, and that
knowledge did not change our donor selection criteria.
Dr Thomas M. Egan (Chapel Hill, NC). I thought every-
one in Denver had PHTN, and I raise the issue because I am
curious as to what proportion of patients who undergo lobec-
tomy for lung cancer or some other pulmonary resection
would have PAPs in that range. I would not think that you
would define that PAP as being so unusual in Denver. 
What would you do with someone with pulmonary fibrosis
with a PAP of 80/50 mm Hg and a mean of 65 mm Hg? You
did not have any patients with severe PHTN, but many of the
patients whom we see with pulmonary fibrosis, and in partic-
ular sarcoidosis, have significant elevation of PAP. What do
you do with those patients?
Dr Huerd. I do not believe everyone in Denver has elevat-
ed PAPs. What we see routinely is that the PAPs in patients
in Denver are exactly the same as anywhere else and that
there have been no data from our institution that have shown
that patients at a higher elevation have a higher inherent pres-
sure. 
To answer your question about someone with idiopathic
pulmonary fibrosis and a mean PAP of 65 mm Hg, we actu-
ally would consider that patient with a mean PAP above 60
mm Hg to have enough elevated pressures that we would pro-
ceed with a DLT in that particular population. We were focus-
ing mostly on patients who have what we would consider
moderate secondary PHTN, and based on recent abstracts
that have been submitted, we believe that it is really not an
independent variable to predict a poor outcome for a patient
who undergoes an SLT. 
Dr Walter Klepetko (Vienna, Austria). You have men-
tioned a higher infection rate in the patients with secondary
PHTN. However, this difference did not reach statistical sig-
nificance. Have you done any analysis as to whether these
infections derived from the native lung or the transplanted
lung? One could assume that the native lung in patients with
moderate PHTN who have undergone transplantation will
receive less pulmonary blood flow than the transplanted lung
and therefore might be more susceptible to infection.
Dr Huerd. No, we have not looked specifically at the
source of the infection, but we would infer, based on what Dr
Starnes had commented on earlier, that flow between the allo-
graft and the native lung is probably equally distributed since
our mean pressures were in the 30 to 39 mm Hg range. I
would assume that flow would be nearly equivalent between
the two sides and that we could not predict higher native lung
infection rates. 
